Phase II NALIRIFOX in Advanced Unresectable Small Bowel Tumors (MMRp/MSS)

This H. Lee Moffitt Cancer Center phase II outpatient study is evaluating NALIRIFOX—combining nanoliposomal irinotecan (a topoisomerase I inhibitor), oxaliplatin, 5-FU, and leucovorin—in advanced unresectable small bowel adenocarcinoma with MMRp and/or MSS profiles. Patients receive treatment on Days 1 and 15 of a 28-day cycle for up to 6 cycles, with the option for de-escalated maintenance based on response.